Which has stronger earnings and valuation, CDXS or GERN?

Codexis has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 3.31 -$43.97M -$0.37 N/A Geron $183.88M 4.17 -$83.50M -$0.11 N/A

Is CDXS or GERN more profitable?

Geron has a net margin of -35.48% compared to Codexis' net margin of -40.97%. Geron's return on equity of -23.31% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -40.97% -68.09% -23.72% Geron -35.48% -23.31% -10.08%

Codexis (CDXS) Competitors

$2.56 +0.07 (+2.81%)

As of 09:39 AM Eastern

Compare

CDXS vs. LXRX, GERN, ACHV, RIGL, and IRWD

Should you buy Codexis stock or one of its competitors? MarketBeat compares Codexis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Codexis include Lexicon Pharmaceuticals (LXRX), Geron (GERN), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does Codexis compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 1 mentions for Codexis. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Codexis' score of 0.43 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Codexis	Neutral

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Codexis has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market.

Codexis has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.97	-$50.34M	-$0.07	N/A
Codexis	$70.39M	3.31	-$43.97M	-$0.37	N/A

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Codexis' net margin of -40.97%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Codexis	-40.97%	-68.09%	-23.72%

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, suggesting a potential upside of 125.81%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 95.31%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lexicon Pharmaceuticals beats Codexis on 11 of the 16 factors compared between the two stocks.

How does Codexis compare to Geron?

Codexis (NASDAQ:CDXS) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Codexis has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Geron has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Codexis presently has a consensus target price of $5.00, indicating a potential upside of 95.31%. Geron has a consensus target price of $2.50, indicating a potential upside of 109.21%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Codexis had 1 more articles in the media than Geron. MarketBeat recorded 1 mentions for Codexis and 0 mentions for Geron. Geron's average media sentiment score of 1.87 beat Codexis' score of 0.43 indicating that Geron is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Geron	Very Positive

Codexis has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.31	-$43.97M	-$0.37	N/A
Geron	$183.88M	4.17	-$83.50M	-$0.11	N/A

Geron has a net margin of -35.48% compared to Codexis' net margin of -40.97%. Geron's return on equity of -23.31% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Geron	-35.48%	-23.31%	-10.08%

Summary

Geron beats Codexis on 9 of the 15 factors compared between the two stocks.

How does Codexis compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Achieve Life Sciences presently has a consensus price target of $14.67, suggesting a potential upside of 164.69%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 95.31%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Achieve Life Sciences is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Codexis had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 1 mentions for Codexis and 0 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.87 beat Codexis' score of 0.43 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Achieve Life Sciences	Very Positive
Codexis	Neutral

Achieve Life Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Codexis has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Codexis	-40.97%	-68.09%	-23.72%

Codexis has higher revenue and earnings than Achieve Life Sciences. Codexis is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Codexis	$70.39M	3.31	-$43.97M	-$0.37	N/A

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Codexis beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Codexis compare to Rigel Pharmaceuticals?

Codexis (NASDAQ:CDXS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

78.5% of Codexis shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Codexis currently has a consensus price target of $5.00, indicating a potential upside of 95.31%. Rigel Pharmaceuticals has a consensus price target of $54.50, indicating a potential upside of 64.43%. Given Codexis' higher possible upside, equities analysts plainly believe Codexis is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.31	-$43.97M	-$0.37	N/A
Rigel Pharmaceuticals	$299.77M	2.05	$367.02M	$18.72	1.77

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for Codexis. Rigel Pharmaceuticals' average media sentiment score of 0.63 beat Codexis' score of 0.43 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Rigel Pharmaceuticals	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to Codexis' net margin of -40.97%. Rigel Pharmaceuticals' return on equity of 47.99% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Codexis has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Codexis on 12 of the 16 factors compared between the two stocks.

How does Codexis compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for Ironwood Pharmaceuticals and 1 mentions for Codexis. Ironwood Pharmaceuticals' average media sentiment score of 1.31 beat Codexis' score of 0.43 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ironwood Pharmaceuticals	Positive
Codexis	Neutral

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 69.61%. Codexis has a consensus target price of $5.00, suggesting a potential upside of 95.31%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Codexis' net margin of -40.97%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Codexis	-40.97%	-68.09%	-23.72%

78.5% of Codexis shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Codexis has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.02	$24.02M	$0.60	6.13
Codexis	$70.39M	3.31	-$43.97M	-$0.37	N/A

Summary

Ironwood Pharmaceuticals beats Codexis on 13 of the 17 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$232.70M	$3.39B	$6.48B	$12.35B
Dividend Yield	N/A	2.27%	2.67%	5.65%
P/E Ratio	-6.92	19.31	23.88	24.26
Price / Sales	3.31	311.64	527.52	106.55
Price / Cash	N/A	125.07	44.13	56.68
Price / Book	4.57	8.01	10.38	6.69
Net Income	-$43.97M	$23.89M	$3.56B	$337.12M
7 Day Performance	8.94%	1.96%	0.87%	2.13%
1 Month Performance	4.07%	-0.39%	1.53%	3.61%
1 Year Performance	15.32%	47.71%	26.44%	29.76%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	2.0466 of 5 stars	$2.56 +2.8%	$5.00 +95.3%	+10.7%	$232.70M	$70.39M	N/A	250	Gap Up
LXRX Lexicon Pharmaceuticals	1.8577 of 5 stars	$1.89 +0.5%	$4.55 +140.7%	+191.0%	$835.09M	$69.64M	N/A	140	Positive News
GERN Geron	2.2985 of 5 stars	$1.14 +3.2%	$2.50 +120.3%	-23.9%	$705.67M	$183.88M	N/A	70	High Trading Volume
ACHV Achieve Life Sciences	2.674 of 5 stars	$5.52 -4.0%	$14.67 +165.7%	+79.0%	$590.29M	N/A	N/A	20	Positive News High Trading Volume
RIGL Rigel Pharmaceuticals	3.1032 of 5 stars	$32.08 +3.8%	$54.50 +69.9%	+58.9%	$571.90M	$294.28M	1.71	160	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. LXRX, GERN, ACHV, RIGL, and IRWD

How does Codexis compare to Lexicon Pharmaceuticals?

Summary

How does Codexis compare to Geron?

Summary

How does Codexis compare to Achieve Life Sciences?

Summary

How does Codexis compare to Rigel Pharmaceuticals?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. LXRX, GERN, ACHV, RIGL, and IRWD

How does Codexis compare to Lexicon Pharmaceuticals?

Does the media favor LXRX or CDXS?

Which has more volatility & risk, LXRX or CDXS?

Which has higher earnings & valuation, LXRX or CDXS?

Do institutionals and insiders hold more shares of LXRX or CDXS?

Is LXRX or CDXS more profitable?

Do analysts rate LXRX or CDXS?

Summary

How does Codexis compare to Geron?

Do insiders and institutionals believe in CDXS or GERN?

Which has more risk and volatility, CDXS or GERN?

Do analysts prefer CDXS or GERN?

Does the media refer more to CDXS or GERN?

Which has stronger earnings and valuation, CDXS or GERN?

Is CDXS or GERN more profitable?

Summary

How does Codexis compare to Achieve Life Sciences?

Do analysts prefer ACHV or CDXS?

Does the media favor ACHV or CDXS?

Which has more volatility and risk, ACHV or CDXS?

Is ACHV or CDXS more profitable?

Which has preferable earnings and valuation, ACHV or CDXS?

Do institutionals & insiders hold more shares of ACHV or CDXS?

Summary

How does Codexis compare to Rigel Pharmaceuticals?

Do institutionals and insiders have more ownership in CDXS or RIGL?

Do analysts recommend CDXS or RIGL?

Which has better earnings & valuation, CDXS or RIGL?

Does the media refer more to CDXS or RIGL?

Is CDXS or RIGL more profitable?

Which has more volatility and risk, CDXS or RIGL?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Does the media prefer IRWD or CDXS?

Do analysts prefer IRWD or CDXS?

Is IRWD or CDXS more profitable?

Do insiders & institutionals hold more shares of IRWD or CDXS?

Which has more volatility & risk, IRWD or CDXS?

Which has higher valuation and earnings, IRWD or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools